Trial Profile
A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Longeveron
- 14 Apr 2022 According to a Longeveron media release, data from this study will be presented at 3rd Latinos & Alzheimers Symposium
- 31 Mar 2022 Results published in the Longeveron Media Release.
- 31 Mar 2022 According to a Longeveron media release, results from the study were published in the Alzheimer's & Dementia: The Journal of the Alzheimer's Association.